In conclusion, the use of PB cfDNA provides a minimally invasive, but informative and sensitive tool for the assessment of mutational status of MYD88 and CXCR4 of patients with IgM monoclonal gammopathies. This evidence concerns the gene CXCR4 and monoclonal gammopathy.